PathAI, Inc., a global leader in artificial intelligence (AI)-powered pathology solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation ...
The latest milestone follows PathAI’s 510(k) clearance for AISight Dx, the first FDA-approved digital pathology system.
CLEVELAND, March 10, 2026 /PRNewswire/ -- GenomOncology, a leading precision medicine software company, today announced a strategic partnership with WeTrials, an AI-powered patient engagement and ...